1,846 件 ・ 関連度順
概要と使いどころ
Diagnose why a PostHog endpoint is slow or expensive and propose a concrete fix — bump the cache TTL, enable materialisation, restructure variables, or rewrite the query. Use when the user says "this endpoint is slow", "my endpoint times out", "we're hitting the cost cap on this one", or asks "should I materialise this?". Focuses on a single named endpoint, not a project-wide audit.
日本語の概要は準備中です。原文の説明を表示しています。
Author useful, low-noise log alerts on services in a PostHog project. Use when the user asks to set up alerts for their logs, suggest alerts they should add, or evaluate whether a service is worth monitoring. Covers service triage, baseline characterisation, threshold drafting, back-testing via simulate, and shipping with a notification destination.
日本語の概要は準備中です。原文の説明を表示しています。
Audit every endpoint in a PostHog project for staleness, failed materialisations, and unused materialised versions. Use when the user asks "what endpoints can I clean up?", "are any of my endpoints broken?", "which materialised versions are still being called?", or wants a one-shot cleanup pass over the Endpoints product. Produces a prioritised report grouped by issue type, with recommended actions but does not modify anything without explicit confirmation.
日本語の概要は準備中です。原文の説明を表示しています。
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
日本語の概要は準備中です。原文の説明を表示しています。
Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.
日本語の概要は準備中です。原文の説明を表示しています。
Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Designs genomics experiments so technical nuisance variation (batch, lane, plate, flow cell, operator, reagent lot, processing day) is balanced against the biological variable of interest and therefore estimable rather than confounded, using constrained sample-to-batch assignment (designit, OSAT), the confounder/mediator/collider distinction, and the principle that no post-hoc correction recovers a fully confounded design. Covers detecting hidden batches with surrogate variable analysis, a decision table for downstream correction (ComBat-seq, RUVSeq, SVA) whose execution is deferred to differential-expression/batch-correction, and reproducibility metadata. Use when assigning samples to sequencing batches/lanes/plates, avoiding batch-condition confounding, deciding whether a design is salvageable by correction, choosing a correction method, or estimating the number of hidden batches. For the experimental unit, randomization, and blocking concepts see experimental-design/randomization-blocking.
日本語の概要は準備中です。原文の説明を表示しています。
Explains ML predictions on omics data with SHAP, LIME, and permutation importance, handling the correlated-feature trap, the conditional-vs-interventional Shapley choice, and the attribution-is-not-causation boundary. Use when interpreting an omics classifier, debugging shortcut/batch learning, or deciding whether an attribution ranking can be trusted as biology. For validated feature selection see machine-learning/biomarker-discovery; explanations are not a selection method.
日本語の概要は準備中です。原文の説明を表示しています。
Orchestrates an end-to-end MeRIP-seq / m6A-seq analysis from raw FASTQ to differential m6A peak calls and metagene plots, chaining fastp adapter trimming, STAR splice-aware alignment (NO deduplication for non-UMI MeRIP), deepTools replicate-concordance + IP-enrichment QC, PreSeq saturation curves, exomePeak2 (transcript-aware Poisson GLM) peak calling, optional MACS3 broad-peak cross-check, DRACH motif confirmation as a sanity check (NOT a per-peak filter), exomePeak2 differential calling via the four-BAM-vector interface (bam_ip + bam_input control; bam_treated_ip + bam_treated_input treatment), ChIPseeker annotation, and the canonical Guitar metagene with stop-codon enrichment as the biological QC anchor. Use when running a complete MeRIP analysis from raw reads, when chaining the constituent epitranscriptomics skills (merip-preprocessing -> m6a-peak-calling -> m6a-differential -> modification-visualization), or when wrapping the pipeline in Snakemake / Nextflow.
日本語の概要は準備中です。原文の説明を表示しています。
End-to-end flow, spectral, and mass cytometry (CyTOF) pipeline from raw FCS files to differentially abundant/expressed cell populations. Orchestrates the read -> compensate/unmix -> transform -> QC -> doublet-removal -> cluster-or-gate -> annotate -> diffcyt DA/DS chain with flowCore/CATALYST/diffcyt, branching on instrument type and on clustering-vs-gating. Use when processing a cytometry experiment end-to-end, deciding the pipeline path for an instrument, or wiring the flow-cytometry component skills into one analysis with valid sample-level statistics.
日本語の概要は準備中です。原文の説明を表示しています。
Design AI chatbot conversation flows with fallbacks. TRIGGERS - Use when user needs help with ai-chatbot-flow related tasks.
日本語の概要は準備中です。原文の説明を表示しています。
Generate a professional offer letter PDF with role, compensation, start date, and company details.
日本語の概要は準備中です。原文の説明を表示しています。
Extract employee, employer, gross pay, cotisations, tax, and net pay from French payslips.
日本語の概要は準備中です。原文の説明を表示しています。
Sécurisation d'agents IA contre injections, abus et fuites de données. Se déclenche avec "sécurité agent", "agent security", "prompt injection", "jailbreak", "agent abuse", "guardrails", "safe agent", "sécuriser mon agent", "agent en production sécurisé".
日本語の概要は準備中です。原文の説明を表示しています。
Raccourcir des URLs via is.gd ou v.gd. Use when: l'utilisateur demande de raccourcir une URL, créer un lien court, ou simplifier une URL longue. NOT for: URLs nécessitant une authentification, liens personnalisés avec domaine propre, analytics avancés.
日本語の概要は準備中です。原文の説明を表示しています。
Facilitates conversational discovery to create Architectural Decision Records (ADRs) for non-functional requirements using the ISO/IEC 25010:2023 quality model. Use when the user wants to document quality attributes, NFR decisions, security/performance/scalability architecture, or design systems with measurable quality criteria. This should trigger for requests such as Create ADR for Non-functional requirements; Document Non-functional requirements; Capture Non-functional requirements; Generate Non-functional requirements in an ADR. Part of cursor-rules-java project
日本語の概要は準備中です。原文の説明を表示しています。
給与収入や課税所得からふるさと納税の寄附上限額(自己負担2,000円の目安)を計算する。ふるさと納税、寄附上限、寄附金控除、ワンストップ特例の相談に対応。API不要の純粋計算。確定申告書の作成や個別の税務判断は対象外。
Check, from the employer's side, what has been put in writing before a paid Otameshi Tenshoku assignment starts under gyomu-itaku: item by item whether the deliverable, delivery date, fee and how it is calculated, payment due date, who pays, out-of-scope work, revision limits, company support, rights, confidentiality and termination are stated in a contract, purchase order or email rather than in chat or by word of mouth, count the days from delivery to payment, and find pay tied to satisfaction or hiring, unpaid or unlimited revisions and one-sided termination. Use when a hiring manager, recruiter or small-business owner is about to offer terms to a candidate, has been asked by a candidate what is still unwritten, or needs the conditions written for a platform contract screen; do not use to judge whether the terms are lawful or the fee fair, to compute withholding or consumption tax, for employment contracts, or to sign, send or conclude the contract on the user's behalf.
日本語の概要は準備中です。原文の説明を表示しています。
Debrief a finished Otameshi Tenshoku trial from the employer's side: set the observed facts against the completion criteria agreed before the start, keep expectations added afterwards, second-hand or off-the-job observations and the company's own late or missing support apart, settle the hours actually worked separately from any evaluation, and draft feedback to the candidate that states facts, support gaps and what happens next without promising a hire or continuation the company has not decided. Use when a hiring manager, recruiter or small-business owner wants to review a trial, decide what to tell the candidate, or work out the settlement after a shortfall; do not use to judge the candidate's aptitude or predict a hire, to cut pay or demand unpaid rework because of dissatisfaction, to compare candidates, or to send the feedback, pay, or update records on the user's behalf.
日本語の概要は準備中です。原文の説明を表示しています。
Draft or review an employer's Otameshi Tenshoku listing so a candidate can decide whether to apply: check item by item that the work, deliverable, out-of-scope tasks, required experience, support, hours, schedule, location, compensation, contract form and payment timing are stated, find open-ended, unpaid-company-work, guarantee, personal-attribute and unverifiable wording, and confirm that the hours, weekly availability, period, rate and budget hold together. Use when a hiring manager, recruiter or small-business owner wants a listing written from a plan, wants an existing draft or published listing reviewed before or after posting, or wants to know why applications are not coming; do not use to design the work itself (trial-work-design), to reply to applicants (applicant-reply), to state market rates, legal, tax or service conditions from memory, or to post or update the listing on the user's behalf.
日本語の概要は準備中です。原文の説明を表示しています。
Design what an employer will have a candidate do during an Otameshi Tenshoku trial: turn a business problem into a bounded paid assignment or an unpaid learning visit, with scope, completion criteria, candidate hours, company staff hours, duration, compensation and change conditions, and check the planned cost against the budget. Use when a hiring manager, recruiter or small-business owner wants to decide what work to offer, how much time it takes, what it costs, or how to adjust a plan when materials are late or the scope grows; do not use to write the public listing (trial-listing-draft), to reply to applicants (applicant-reply), to state market rates, legal, tax or service conditions from memory, or to post, contact or contract on the user's behalf.
日本語の概要は準備中です。原文の説明を表示しています。
Use OpenAI Codex CLI as a peer collaboration partner — same standing as Claude, not a one-shot tool. Bring Codex in EARLY (ideation, framing decisions, stuck moments), not only for late peer-review. Hand it strategic context (target, research, draft, reasoning), iterate conversationally over ~3-8 turns, converge before surfacing to the human. Invoke when the user says "check / iterate / ideate with Codex" or "ask Codex" — and proactively when stuck between two reasonable framings, pressure-testing a load-bearing claim or structure, or about to ask the human to pick between options two agents could resolve.
日本語の概要は準備中です。原文の説明を表示しています。
Designs genomics experiments so technical nuisance variation (batch, lane, plate, flow cell, operator, reagent lot, processing day) is balanced against the biological variable of interest and therefore estimable rather than confounded, using constrained sample-to-batch assignment (designit, OSAT), the confounder/mediator/collider distinction, and the principle that no post-hoc correction recovers a fully confounded design. Covers detecting hidden batches with surrogate variable analysis, a decision table for downstream correction (ComBat-seq, RUVSeq, SVA) whose execution is deferred to differential-expression/batch-correction, and reproducibility metadata. Use when assigning samples to sequencing batches/lanes/plates, avoiding batch-condition confounding, deciding whether a design is salvageable by correction, choosing a correction method, or estimating the number of hidden batches. For the experimental unit, randomization, and blocking concepts see experimental-design/randomization-blocking.
日本語の概要は準備中です。原文の説明を表示しています。
Estimates time-scaled phylogenies, molecular clock rates, effective reproduction number R_e (or R_t), and population dynamics from dated pathogen genomes using TreeTime (maximum-likelihood) and BEAST2 (Bayesian; strict / uncorrelated lognormal / ORC clocks; constant / exponential / Bayesian Skyline / Skygrid / BICEPS / Birth-Death-Skyline / sampled-ancestor BDSKY priors; structured coalescent via MASCOT). Covers root-to-tip clock signal QC via TempEst, date-randomisation tests (Ramsden 2009; Duchêne 2015), recombination masking via Gubbins and ClonalFrameML before clock inference for recombining bacteria, BDSKY origin-vs-rootHeight pitfalls, sampling-bias correction (Volz & Frost 2014; preferential-sampling extensions), MASCOT structured coalescent for migration, BICEPS-vs-BSP skyline choice, multi-chain BEAST2 convergence diagnostics, and reconciliation between phylodynamic R_e and case-based R_t. Use when dating outbreak origins, estimating substitution rates, inferring R_e through time, building time-calibrated Nextstrain Augur trees, choosing between strict and relaxed clocks, fitting Birth-Death-Skyline (Stadler 2013) models, diagnosing temporal-signal failure, masking recombination before clock inference for *Streptococcus pneumoniae* / *Neisseria gonorrhoeae* / *Klebsiella* / *E. coli* phylodynamics, running MASCOT for structured-population analyses, or using UShER for pandemic-scale placement.
日本語の概要は準備中です。原文の説明を表示しています。